ANNUAL REPORT FOR THE FINANCIAL YEAR 2024-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd has submitted its 32nd Annual Report for FY 2024-2025 to BSE along with the AGM notice. The 32nd Annual General Meeting is scheduled for Tuesday, 30th September 2025 at 11:00 AM in Indore. Key financials show a decline: total revenue fell to Rs. 2,255.48 lakhs from Rs. 2,712.48 lakhs in FY24, while net profit dropped to Rs. 57.88 lakhs from Rs. 76.86 lakhs. EPS slipped to Rs. 1.14 from Rs. 1.52, and the Board has not recommended any dividend. The notice also seeks shareholder approval for re-appointment of Sudhir Sethi as Director (retiring by rotation) and Sanjay Sethi as Managing Director for another five years, plus the appointment of Dipika Kataria as Secretarial Auditor for a five-year term. The company is listed on BSE and Ahmedabad Stock Exchange, with its registered office in Indore, Madhya Pradesh.
Declining revenue and profit year-on-year, combined with no dividend payout, may be viewed negatively by investors looking for growth or income. The re-appointments signal continuity in leadership, but the weak performance numbers are likely the main concern for shareholders.